PT-141
Research/community name linked to bremelanotide — for the approved use, see Vyleesi.
What it's for
PT-141 is a widely used research and community name for bremelanotide (a melanocortin signal turn-on medicine). The FDA-approved medicine that contains bremelanotide is Vyleesi.
What it does for the body
As approved bremelanotide, the medicine treats low sexual desire with distress in premenopausal women. Unapproved PT-141 products sold as research chemicals are not the same as the approved drug and are not FDA-authorized therapies.
What it targets
Same core action as bremelanotide: turning on melanocortin receptors (landing spots on cells) that influence brain pathways for sexual arousal. Picture lock-and-key on those brain pathways. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: PT-141 is best treated as a research-interest topic. Early papers can be fascinating; they are not a green light for self-experimentation.
Studied for (literature interest)
- Brain research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: PT-141 — FDA.gov search
- ClinicalTrials.gov search: PT-141 — U.S. clinical trials registry
- Drugs@FDA search: PT-141 — FDA drug database (if approved)
- PubMed search: PT-141 — NCBI PubMed
- PubMed Central search: PT-141 — NCBI PMC
Reference
Ref $49 ref only